Abstract

This study aimed to evaluate the association of genetic variants in lactoferrin (LTF) metabolism-related genes with the prevalence of metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUHO). In total, 161 MHO and 291 MUHO subjects were recruited to the study. The following polymorphisms were genotyped: low-density lipoprotein receptor-related protein (LRP) 2 rs2544390, LRP1 rs4759277, LRP1 rs1799986, LTF rs1126477, LTF rs2239692 and LTF rs1126478. We found significant differences in the genotype frequencies of LTF rs2239692 between MHO and MUHO subjects, with the CT variant associated with lower odds of developing metabolic syndrome than the TT variant. In the total population, significant differences in body weight and waist circumference (WC) were identified between LTF rs1126477 gene variants. A similar association with WC was observed in MUHO subjects, while significant differences in body mass index and low-density lipoprotein cholesterol levels were discovered between LTF rs1126477 gene variants in MHO subjects. Besides, there were significant differences in diastolic blood pressure between LRP1 rs1799986 gene variants in MUHO subjects, as well as in WC and high-density lipoprotein cholesterol levels between LRP1 rs4759277 gene variants in MHO subjects. In conclusion, selected lactoferrin and lactoferrin receptor-related gene variants may be associated with the prevalence of metabolically healthy or metabolically unhealthy obesity.

Highlights

  • Obesity is an important global health problem

  • Obesity increases the risk of developing cardiovascular diseases, hypertension, dyslipidaemia and several other abnormalities associated with the development of metabolic syndrome [3]

  • Previous studies suggested that selected polymorphisms in LTF, lipoprotein receptor-related protein 1 (LRP1), and lipoprotein receptor-related protein 2 (LRP2) genes might be associated with the prevalence of metabolic abnormalities [7,11,12,23,24,25,26]

Read more

Summary

Introduction

Obesity is an important global health problem. According to the World Health Organization (WHO), obesity prevalence rates tripled between 1975 and 2016, and currently, around 650 million people worldwide (15% of women and 11% of men aged ≥18 years) suffer from excessive body weight [1]. Obesity is a cosmetic defect but can cause a variety of metabolic abnormalities, Nutrients 2020, 12, 2843; doi:10.3390/nu12092843 www.mdpi.com/journal/nutrients. It is well known that excessive body weight is associated with insulin resistance and hyperinsulinemia. Obesity is recognised as an important risk factor in the pathogenesis of type 2 diabetes mellitus [2]. Obesity increases the risk of developing cardiovascular diseases, hypertension, dyslipidaemia and several other abnormalities associated with the development of metabolic syndrome [3]

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call